Condition: Immune-related Adverse Event · Neoadjuvant Therapy · dMMR Colorectal Cancer · Sponsor: Xijing Hospital
This study aims to explore the optimal number of cycles of PD-1 monotherapy required at minimum, under the premise of ensuring pathological complete response (pCR) among patients with dMMR/MSI-H rectal cancer. Participants will receive preoperative monotherapy with PD-1 antibodies, with regular reassessments every 2 cycles. Surgical intervention will be performed if clinical complete response (cCR) is achieved. Researchers will compare the pathological complete response rates, adverse reactions, and three-year event-free survival rates across different treatment cycles.
This description comes directly from the study's public registry record.
Jipeng Li, Doctor · Jipeng · jipeng1974@aliyun.com
Yihuan Qiao, Doctor · 18682986362 · yhqiao1995@126.com
Always discuss trial participation with your own doctor first.
| Xijing hospital | Xi'an, Shaanxi, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06613165